HOOKIPA Pharma Inc

Capital Structure and Liquidity HOOKIPA maintains a debt-free capital structure with $39.68 million in cash and equivalents, and $51.21 million in total equity, resulting in a debt-to-equity ratio of 0.0. The company's liquidity position is reflected in a current ratio of 3.27, indicating strong short-term liquidity. However, the company reported negative operating cash flow of $76.98 million and free cash flow of $40.94 million, suggesting significant cash outflows from operations. ### Profitability and Returns The company reported a net loss of $43.50 million and an operating loss of $51.46 million, resulting in a return on equity of -84.94% and a return on assets of -52.7%. These figures are below the typical performance metrics for the biotechnology industry, which often includes high R&D expenditures and pre-revenue operations. ### Segments and Geographic Exposure According to disclosed segments, HOOKIPA's revenue is primarily derived from partnerships, particularly with Gilead Sciences Inc, for its Hepatitis B and HIV programs. The company does not provide detailed geographic revenue breakdowns, but its operations are centered in the United States. ### Growth Trajectory The company's recent revenue of $43.95 million reflects a modest level of activity, but the absence of positive operating cash flow and the significant net loss suggest limited near-term growth. The company is currently assessing strategic alternatives, which may influence its future direction. ### Risk Factors The company faces liquidity risk due to its negative operating and free cash flows, although it is currently classified as low risk for dilution and liquidity. The absence of long-term debt and the presence of $39.68 million in cash and equivalents provide a buffer against immediate liquidity pressures. ### Recent Events Recent filings and transcripts indicate that HOOKIPA is engaged in the assessment of strategic alternatives and the development of infectious disease therapies in partnership with other companies. The company's focus on partnerships, particularly with Gilead Sciences Inc, is a key strategic element.